177 related articles for article (PubMed ID: 25420481)
1. Candesartan stimulates reparative angiogenesis in ischemic retinopathy model: role of hemeoxygenase-1 (HO-1).
Shanab AY; Elshaer SL; El-Azab MF; Soliman S; Sabbineni H; Matragoon S; Fagan SC; El-Remessy AB
Angiogenesis; 2015 Apr; 18(2):137-50. PubMed ID: 25420481
[TBL] [Abstract][Full Text] [Related]
2. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
Nakamura S; Tsuruma K; Shimazawa M; Hara H
Eur J Pharmacol; 2012 Jun; 685(1-3):8-14. PubMed ID: 22543084
[TBL] [Abstract][Full Text] [Related]
3. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy.
DeNiro M; Al-Halafi A; Al-Mohanna FH; Alsmadi O; Al-Mohanna FA
Mol Pharmacol; 2010 Mar; 77(3):348-67. PubMed ID: 20008515
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart.
Siddiqui AJ; Mansson-Broberg A; Gustafsson T; Grinnemo KH; Dellgren G; Hao X; Fischer H; Sylvén C
Am J Hypertens; 2005 Oct; 18(10):1347-52. PubMed ID: 16202860
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M
Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771
[TBL] [Abstract][Full Text] [Related]
7. Candesartan ameliorates acute myocardial infarction in rats through inducible nitric oxide synthase, nuclear factor‑κB, monocyte chemoattractant protein‑1, activator protein‑1 and restoration of heat shock protein 72.
Lin X; Wu M; Liu B; Wang J; Guan G; Ma A; Zhang Y
Mol Med Rep; 2015 Dec; 12(6):8193-200. PubMed ID: 26499133
[TBL] [Abstract][Full Text] [Related]
8. Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke.
Soliman S; Ishrat T; Fouda AY; Patel A; Pillai B; Fagan SC
Transl Stroke Res; 2015 Aug; 6(4):309-22. PubMed ID: 26004281
[TBL] [Abstract][Full Text] [Related]
9. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
10. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
11. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
12. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.
Alhusban A; Kozak A; Ergul A; Fagan SC
J Pharmacol Exp Ther; 2013 Feb; 344(2):348-59. PubMed ID: 23211364
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-responsive microRNA-101 promotes angiogenesis via heme oxygenase-1/vascular endothelial growth factor axis by targeting cullin 3.
Kim JH; Lee KS; Lee DK; Kim J; Kwak SN; Ha KS; Choe J; Won MH; Cho BR; Jeoung D; Lee H; Kwon YG; Kim YM
Antioxid Redox Signal; 2014 Dec; 21(18):2469-82. PubMed ID: 24844779
[TBL] [Abstract][Full Text] [Related]
14. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Kozak A; Ergul A; El-Remessy AB; Johnson MH; Machado LS; Elewa HF; Abdelsaid M; Wiley DC; Fagan SC
Stroke; 2009 May; 40(5):1870-6. PubMed ID: 19265050
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy.
Al-Shabrawey M; Bartoli M; El-Remessy AB; Platt DH; Matragoon S; Behzadian MA; Caldwell RW; Caldwell RB
Am J Pathol; 2005 Aug; 167(2):599-607. PubMed ID: 16049343
[TBL] [Abstract][Full Text] [Related]
17. Shifts in renin-angiotensin system components, angiogenesis, and oxidative stress-related protein expression in the lamina cribrosa region of streptozotocin-induced diabetic mice.
Qian X; Lin L; Zong Y; Yuan Y; Dong Y; Fu Y; Shao W; Li Y; Gao Q
Graefes Arch Clin Exp Ophthalmol; 2018 Mar; 256(3):525-534. PubMed ID: 29404759
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth.
Fujita M; Hayashi I; Yamashina S; Fukamizu A; Itoman M; Majima M
Carcinogenesis; 2005 Feb; 26(2):271-9. PubMed ID: 15637093
[TBL] [Abstract][Full Text] [Related]
19. [Aging and retinal vascular diseases].
Takagi H
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):207-30; discussion 231. PubMed ID: 17402563
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
